Cocrystal Pharma, Inc.

TUCKER, GA · Biotech · Public

Structure-based antiviral drug therapeutics targeting viral replication

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cocrystalpharma.com

Sector: Biotech
Headquarters: TUCKER, GA
Latest Form D: $3M, May 2017
Total capital: $29.4M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $28.9M; 17 Form D · last May 2017; 114 months since last filing
Federal contracts: $498K; 1 award · Health and Human S; Rank in Biotech#232 of 4373
Granted patents: 9; 31 pending · first 2019; Rank in peer group#179 of 1449

Capital timeline

Latest events

Sep 2025Federal contractHealth and Human S · Development Of Pan-influenza Inhibitors Targeting The Pa Endonuclease From The Viral Replication Complex$498K
May 2017Private capital raisedForm D · SEC · 16th filing$3M
Sep 2016Private capital raisedForm D · SEC · 15th filing$4M
Mar 2016Private capital raisedForm D · SEC · 14th filing$5M
Jan 2014Private capital raisedForm D · SEC · 13th filing$2.8M
Nov 2013Private capital raisedForm D · SEC · 12th filing$3.5M
Sep 2013Private capital raisedForm D · SEC · 11th filing$2M
Apr 2013Private capital raisedForm D · SEC · 10th filing$800K
Jun 2012Private capital raisedForm D · SEC · 9th filing$200K
May 2012Private capital raisedForm D · SEC · 8th filing$250K
Apr 2012Private capital raisedForm D · SEC · 7th filing$2.3M
Apr 2012Private capital raisedForm D · SEC · 6th filing$455K
Apr 2012Private capital raisedForm D · SEC · 5th filing$500K
Apr 2012Private capital raisedForm D · SEC · 4th filing$250K
Mar 2012Private capital raisedForm D · SEC · 3rd filing$1M
Mar 2012Private capital raisedForm D · SEC · 2nd filing$2.3M
Jan 2012Private capital raisedForm D · SEC · 1st filing$650K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#179 · top 12%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

CURTIS A DALEExecutive OfficerNamed in SEC Form D filings
David S. BlockDirectorNamed in SEC Form D filings
DOUGLAS L MAYERSExecutive OfficerNamed in SEC Form D filings
Gary WilcoxExecutive Officer, DirectorNamed in SEC Form D filings
James F. MartinExecutive OfficerNamed in SEC Form D filings
Jane H. HsiaoDirectorNamed in SEC Form D filings

Show all 12 people

JEFFREY A MECKLERExecutive Officer, DirectorNamed in SEC Form D filings
PHILLIP A FROSTDirectorNamed in SEC Form D filings
Raymond F. SchinaziDirectorNamed in SEC Form D filings
Sam F. LeeExecutive OfficerNamed in SEC Form D filings
STEVEN D RUBINDirectorNamed in SEC Form D filings
WALT ADDISON LINSCOTTExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 9 granted of 40

Jun 9, 2026GrantedInhibitors Of Norovirus And Coronavirus ReplicationUSPTOUS 12,649,715
Mar 3, 2026GrantedInhibitors Of Influenza Virus ReplicationUSPTOUS 12,565,488
Jul 17, 2025PendingPolycyclic Cap-dependent Endonuclease Inhibitors For Treating Or Preventing InfluenzaUSPTOApplication 18682331

Show all 40 patent records

Inhibitors Of Norovirus And Coronavirus ReplicationJun 9, 2026 · US 12,649,715Granted
Inhibitors Of Influenza Virus ReplicationMar 3, 2026 · US 12,565,488Granted
Polycyclic Cap-dependent Endonuclease Inhibitors For Treating Or Preventing InfluenzaJul 17, 2025 · Application 18682331Pending
PYRROLO[2,3-B]PYRIDIN Derivatives As Inhibitors Of Influenza Virus ReplicationJul 15, 2025 · US 12,357,631Granted
Combinations Of Inhibitors Of Influenza Virus ReplicationFeb 25, 2025 · US 12,233,066Granted
Inhibitors For CoronavirusesDec 5, 2024 · Application 18292989Pending
Formulations Of Influenza TherapeuticsDec 3, 2024 · US 12,156,876Granted
Polycyclic Cap-dependent Endonuclease Inhibitors For Treating Or Preventing InfluenzaJan 18, 2024 · Application 18015465Pending
Combination Therapy For Treatment Of HcvSep 12, 2023 · US 11,752,166Granted
Inhibitors Of Norovirus And Coronavirus ReplicationMay 25, 2023 · Application 17912749Pending
Peptidomimetic N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE Derivatives, TRIAZASPIRO[4.14]NONADECANE Derivatives And Similar Compounds As Inhibitors Of Norovirus And Coronavirus ReplicationMay 18, 2023 · Application 17911461Pending
Pyrrolopyrimidine Derivatives Useful As Inhibitors Of Influenza Virus ReplicationMay 25, 2021 · US 11,014,941Granted
Inhibitors Of Hepatitis C Virus PolymeraseMar 16, 2021 · US 10,947,210Granted
Inhibitors Of Hepatitis C Virus PolymeraseNov 5, 2019 · US 10,464,914Granted
Formulations Of Influenza TherapeuticsApplication PCTUS2019061065Pending
Inhibitors O Finfluenza Virus ReplicationApplication PCTUS2019043549Pending
Combination Therapy For Treatment Of HcvApplication PCTUS2019031459Pending
Inhibitors Of Influenza Virus ReplicationApplication 62771283Pending
Formulations Of Influenza TherapeuticsApplication 62760121Pending
Combinations Of Inhibitors Of Influenza Virus ReplicationApplication 62746884Pending
Inhibitors Of Influenza Virus ReplicationApplication 62729190Pending
Inhibitors Of Influenza Virus ReplicationApplication 62711177Pending
Combination Therapy For Treatment Of HcvApplication 62669007Pending
Inhibitors Of Infulenza Virus ReplicationApplication PCTUS2018028986Pending
Inhibitors Of Influenza Virus ReplicationApplication 62489167Pending
Inhibitors Of Hepatitis C Virus PolymeraseApplication PCTUS2016023664Pending
Inhibitors Of Hepatitis C Virus PolymeraseApplication 62136857Pending
Inhibitors For CoronavirusesApplication PCTUS2022039233Pending
Polycyclic Cap-dependent Endonuclease Inhibitors For Treating Or Preventing InfluenzaApplication 63231871Pending
Inhibitors For CoronavirusesApplication 63228908Pending
Polycyclic Cap-dependent Endonuclease Inhibitors For Treating Or Preventing InfluenzaApplication PCTUS2021042711Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication PCTUS2021022657Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication PCTUS2021022680Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication PCTUS2021022656Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication 63027492Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication 63027495Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication 63008195Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication 63008183Pending
Inhibitors Of Norovirus And Coronavirus ReplicationApplication 62990721Pending
Inhibitors Of Influenza Virus ReplicationApplication PCTUS2019063167Pending

Hafion Inc.Similar federal contract value in Biotech · $536K in contracts
BrainXell, IncSimilar federal contract value in Biotech · $516K in contracts
VASCUMAB LLCSimilar federal contract value in Biotech · $502K in contracts
Mirum PharmaceuticalsSimilar federal contract value in Biotech · $460K in contracts
ARIMA GENOMICS, INC.Similar federal contract value in Biotech · $457K in contracts
APPLIED BIOTECHNOLOGY INSTITUTESimilar federal contract value in Biotech · $450K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.